CJC-1295 + Ipamorelin — Research Profile
The CJC-1295 + Ipamorelin blend pairs a long-acting GHRH analogue (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin). Research has explored their combined action on pulsatile growth-...
Overview
The CJC-1295 + Ipamorelin blend pairs a long-acting GHRH analogue (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin). Research has explored their combined action on pulsatile growth-hormone release and IGF-1 dynamics in preclinical and clinical models.
History
Both peptides emerged from somatotropic-axis research in the 1990s–2000s. The blend is studied in research models because the two compounds engage complementary upstream pathways (GHRH receptor + ghrelin receptor), producing additive effects on GH release in animal studies.
CJC-1295 (DAC) Structure
- CAS #: 863288-34-0
- Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
- Molecular Weight: 3367.97 g/mol
- PubChem ID: 16133122
Ipamorelin Structure
- CAS #: 170851-70-4
- Molecular Formula: C₃₈H₄₉N₉O₅
- Molecular Weight: 711.85 g/mol
- PubChem ID: 11375645
Research Findings
Combined administration of GHRH analogues and ghrelin-receptor agonists has been studied for synergistic effects on GH pulsatility, IGF-1 levels, and somatotropic-axis dynamics.
Key Areas of Research
- Somatotropic: GHRH-R + GHSR co-activation
- Endocrine: pulsatile GH release studies
- IGF axis: downstream IGF-1 dynamics
The combination is a frequent subject in research on multi-pathway somatotropic activation.
References
- [1]Teichman S. L. et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. (2006).
- [2]Raun K. et al. Ipamorelin, the first selective growth hormone secretagogue. (1998).
All references link to the corresponding PubMed record. Citations maintained for transparency — Viora articles are sourced from the published research literature.